Clinical Trial: Study on the Mechanism by which SLC38A4 promotes aerobic glycolysis and cancer progression in gastric cancer cells through the FKBP10-mediated AKT pathway (China)

Posted On: 2026-10-12

China, Oct. 12 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Study on the Mechanism by which SLC38A4 promotes aerobic glycolysis and cancer progression in gastric cancer cells through the FKBP10-mediated AKT pathway'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600134169

Registration Time: 2026/10/11

Type: Observational study

Primary Sponsor: Chongqing General Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=304405

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Study on the Mechanism by which SLC38A4 promotes aerobic glycolysis and cancer progression in gastric cancer cells through the FKBP10-mediated AKT pathway (China)